We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Screening Cancer Patients for Lynch Syndrome Extends Lives

By LabMedica International staff writers
Posted on 28 Jul 2011
Screening every new colon cancer patient for a familial disorder called Lynch syndrome extends lives at a reasonable cost.

Lynch syndrome is caused by mutations in a set of genes that normally run quality control on the DNA of cells. More...
The loss of such a molecular DNA inspector predisposes Lynch syndrome patients to tumor growth. Unusual patterns in the DNA of tumor cells or a missing inspector indicate that there is diminished quality control. As soon as a pathologist identifies a tumor that might be caused by the disorder, more tests are needed to determine if the patient carries a particular mutation.

The most cost-effective method involved checking whether tumors were missing any molecular quality inspectors, followed by DNA sequencing of the suspected gene.

Approximately 3% to 5% of colorectal tumors are caused by Lynch syndrome, which greatly increases the odds of colon and other cancers in a person's lifetime. Siblings and children of someone with Lynch syndrome each have a 50% chance of carrying the mutation, so the first diagnosis in a family reveals the risk for many relatives.

"This is a situation where, if you find out genetic information, you can improve your outcome," said Uri Ladabaum, MD, associate professor of gastroenterology and hepatology at the Stanford University School of Medicine (Stanford, CA, USA) and lead author of the study. Lynch syndrome patients can take defensive steps (such as yearly colonoscopies) that can either prevent cancer or alert them to get cancer treatment early, when it has the best chance of working.

Prof. Ladabaum and colleagues used computer simulations to compare the years of lives gained and the money spent if all new cases of colorectal cancer were tested for Lynch syndrome. They found that such screening programs could reduce cancer deaths at a price within the typical range of US healthcare costs. The study was published in the July 19, 2011, issue of Annals of Internal Medicine.

Prior to the availability of genetic testing, Lynch syndrome was identified by observant genetic counselors and physicians who noticed the high frequency of cancers in certain families. However, this method is not foolproof, especially if a patient does not know his or her family history. If Lynch syndrome is present a person's lifetime risk of developing colon cancer increases from 5% to 70%.

The study suggests that more medical centers could adopt tumor-screening policies like Stanford's. "A systematic approach to identify families with Lynch syndrome makes sense clinically, because it can save lives, and economically, because its costs are comparable to other things we choose to spend our healthcare dollars on," said Prof. Ladabaum. "We advocate establishing similar tumor-screening systems on a national level."

Related Links:
Stanford University School of Medicine




Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Automated Clinical Chemistry Analyzer
Envoy 500+
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Microbiology

view channel
Image: Graphical Abstract (Emery, J. K., V. Nemidkanam, N. Colon, et al. Journal of Extracellular Vesicles (2026). https://doi.org/10.1002/jev2.70286)

Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori

Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.